Single Autoantibody: What It Means When Your Child Tests Positive for One Type 1 Marker

When doctors screen children for Type 1 diabetes risk, they look for autoantibodies—proteins the immune system makes that mistakenly attack the insulin-producing cells in the pancreas. Most children who develop Type 1 diabetes eventually have two or more of these autoantibodies. But what happens when a child tests positive for just one?

A new case series from Bulgaria followed seven children who had a single autoantibody but no signs of diabetes. The researchers measured five well-known Type 1 diabetes autoantibodies: anti-GAD65, anti-IA2, anti-ZnT8, ICA, and IAA. Over 3 to 6 months, they tracked whether these children's autoantibody levels changed and whether they developed any blood sugar problems.

Among the seven single-positive children, anti-GAD65 was the most frequently detected autoantibody (three children), followed by anti-ZnT8 (two children), anti-IA2 (one child), and IAA (one child).

During the follow-up period, none of the children developed a second autoantibody. All maintained normal blood glucose levels and normal C-peptide (a marker of insulin production). This is encouraging because developing multiple autoantibodies is typically associated with progression toward diabetes diagnosis.

The autoantibody titers—the amounts of these antibodies in the blood—behaved differently in each child. Two children showed what appeared to be seroreversion (disappearance of the autoantibody), one showed a substantial drop in titer, one showed minimal change, and three showed mild increases. Despite these variations, none progressed to diabetes.

All seven children received counseling about lifestyle modifications, including a low-glycemic-index diet and at least 60 minutes of daily physical activity. However, because this was a small case series without a comparison group, the study cannot determine whether these lifestyle changes prevented progression or whether the children's single-positive status naturally follows a non-progressive course in some cases.

The researchers acknowledge an important limitation: one child's apparent seroreversion may have been influenced by immunosuppressive medication taken for an unrelated condition, making it harder to interpret that individual result.

While these short-term findings are reassuring, the authors emphasize that longer follow-up is needed to understand the full natural history of single autoantibody positivity. This small study suggests that not all single-positive children progress rapidly, but more research is necessary to identify which children will remain stable and which may eventually develop additional autoantibodies or Type 1 diabetes.

If your child tests positive for a single Type 1 diabetes autoantibody, this study offers some reassurance: the presence of one autoantibody does not guarantee that diabetes will develop soon. Some children with single positivity may remain stable for extended periods.

At the same time, a single positive autoantibody does indicate increased risk and warrants continued monitoring. Regular follow-up testing and metabolic screening are standard medical practice for children with autoantibody positivity, regardless of whether they have one or multiple autoantibodies. Your child's healthcare team can discuss the best monitoring schedule and answer questions specific to your family's situation.

Source: Life (Basel, Switzerland). Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.